Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C13H22N2O6S
CAS Number:
Molecular Weight:
334.39
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
neostigmine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C
InChI
1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1
InChI key
OSZNNLWOYWAHSS-UHFFFAOYSA-M
Gene Information
human ... ACHE(43)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Neostigmine methyl sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
Reversible inhibitor of acetylcholinesterase; does not cross the blood-brain barrier.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Neostigmine methyl sulfate
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
M O Akinwale et al.
African journal of medicine and medical sciences, 41(2), 231-237 (2012-11-29)
The spinal route of analgesia has consolidated its place as a major modality in the management of both acute and chronic pain. The search for ideal additives to local anaesthetic agents to prolong the analgesic effects poses a challenge to
Tetsufumi Sato et al.
Masui. The Japanese journal of anesthesiology, 62(1), 19-26 (2013-02-26)
Anticholinesterase, such as neostigmine, was used to be a standard drug at the end of surgery for reversal of nondepolarizing neuromuscular block. Neostigmine decreases the metabolism of acetylcholine (ACh) at the neuromuscular junction and allows its concentration to increase and
Global Trade Item Number
| SKU | GTIN |
|---|---|
| N0550000 | 04061833813102 |